Navidea Biopharmaceuticals, Inc. NO1A.F Stock
Navidea Biopharmaceuticals, Inc. Price Chart
Navidea Biopharmaceuticals, Inc. NO1A.F Financial and Trading Overview
Navidea Biopharmaceuticals, Inc. stock price | 0.07 EUR |
Previous Close | 0.05 EUR |
Open | 0.07 EUR |
Bid | 0.07 EUR x N/A |
Ask | 0.1 EUR x N/A |
Day's Range | 0.07 - 0.07 EUR |
52 Week Range | 0.04 - 0.74 EUR |
Volume | 1K EUR |
Avg. Volume | 0 EUR |
Market Cap | 4.07M EUR |
Beta (5Y Monthly) | 1.531338 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.42 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.5 EUR |
NO1A.F Valuation Measures
Enterprise Value | 4.17M EUR |
Trailing P/E | N/A |
Forward P/E | -0.13207547 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 61.919167 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 63.491 |
Enterprise Value/EBITDA | -0.385 |
Trading Information
Navidea Biopharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 1.531338 |
52-Week Change | -93.76% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.74 EUR |
52 Week Low | 0.04 EUR |
50-Day Moving Average | 0.14 EUR |
200-Day Moving Average | 0.22 EUR |
NO1A.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 35.06M |
Float | 25.1M |
Short Ratio | N/A |
% Held by Insiders | 29.41% |
% Held by Institutions | 4.97% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -16665.57% |
Gross Margin | -181.70% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -229.10% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 65.65K EUR |
Revenue Per Share (ttm) | 0.002 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -119295 EUR |
EBITDA | -10840789 EUR |
Net Income Avi to Common (ttm) | -15704126 EUR |
Diluted EPS (ttm) | -0.47 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 33.8K EUR |
Total Cash Per Share (mrq) | 0.001 EUR |
Total Debt (mrq) | 2.32M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.129 |
Book Value Per Share (mrq) | -0.3 |
Cash Flow Statement
Operating Cash Flow (ttm) | -8152581 EUR |
Levered Free Cash Flow (ttm) | -3114554 EUR |
Profile of Navidea Biopharmaceuticals, Inc.
Country | Germany |
State | OH |
City | Dublin |
Address | 4995 Bradenton Avenue |
ZIP | 43017-3552 |
Phone | 614 793 7500 |
Website | https://www.navidea.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 11 |
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Q&A For Navidea Biopharmaceuticals, Inc. Stock
What is a current NO1A.F stock price?
Navidea Biopharmaceuticals, Inc. NO1A.F stock price today per share is 0.07 EUR.
How to purchase Navidea Biopharmaceuticals, Inc. stock?
You can buy NO1A.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Navidea Biopharmaceuticals, Inc.?
The stock symbol or ticker of Navidea Biopharmaceuticals, Inc. is NO1A.F.
Which industry does the Navidea Biopharmaceuticals, Inc. company belong to?
The Navidea Biopharmaceuticals, Inc. industry is Biotechnology.
How many shares does Navidea Biopharmaceuticals, Inc. have in circulation?
The max supply of Navidea Biopharmaceuticals, Inc. shares is 100.08M.
What is Navidea Biopharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Navidea Biopharmaceuticals, Inc. PE Ratio is now.
What was Navidea Biopharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Navidea Biopharmaceuticals, Inc. EPS is -0.42 EUR over the trailing 12 months.
Which sector does the Navidea Biopharmaceuticals, Inc. company belong to?
The Navidea Biopharmaceuticals, Inc. sector is Healthcare.